Drug agency Lupin on January 10 stated it has launched a product, used as an assist to smoking cessation remedy, in the U.S. market.
The firm has launched Varenicline tablets in strengths of 0.5 mg and 1 mg, after having acquired approval from the U.S. Food and Drug Administration (USFDA), the Mumbai-based drug maker stated in a regulatory submitting.
The firm’s product is the generic equal of PF Prism CV’s Chantix tablets, it added.
It is indicated to be used as an assist to smoking cessation remedy.
As per the IQVIA information, Varenicline tablets had estimated annual gross sales of $412 million in the U.S.
Shares of the corporate have been buying and selling 0.75 per cent up at Rs 1,406.50 apiece on the BSE.
